Veltuzumab
Based on 1 Customer Validation
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.69%
- CAS No.: 728917-18-8
- Masse moléculaire:145.34 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG1 kappa
Human
CD20/MS4A1
Veltuzumab significantly reduces off-rates in human lymphoma cell lines, as well as increases complement-dependent cytotoxicity in 1 of 3 cell lines, but no other in vitro differences[1].
Veltuzumab (0.001-10 μg/mL, 3 h) has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:4 lymphoma cell lines (SU-DHL-6, Daudi, Raji and WSU-FSCCL)
-
Concentration:5 μg/mL
-
Incubation Time:4 days
-
Result:Had the sensitivity correlated with CD20 expression (SU-DHL6> Raji > Daudi > WSU-FSCCL).
Veltuzumab (i.p.; 0.05-35 μg) are significantly effective in vivo[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Lymphoma xenograft model[1]
-
Dosage:5, 20 and 60 μg
-
Administration:intraperitoneal and subcutaneous, single
-
Result:Showed low dose of 0.05 μg increased the MST.
-
Animal Model:SCID mice[1]
-
Dosage:0.5, 0.25, 0.1, or 0.05 μg; 35, 3.5, 0.35, or 0.035 μg
-
Administration:intraperitoneal, single
-
Result:Improved significantly survival.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized CD20/MS4A1 Protein, Human can bind Veltuzumab. The EC50 for this effect is 5.793 ng/mL. -
Flow Cytometry analysis of Raji cells labelling CD20/MS4A1 (red) with Veltuzumab (anti-CD20/MS4A1) (HY-P99224). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 728917-18-8
-
Appearance Liquid
-
Masse moléculaire 145.34 kDa
-
Color Colorless to light yellow
-
SMILES
[Veltuzumab]
-
Synonyms
IMMU-106; hA20
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Veltuzumab Related Classifications
HY-P99224 Related Classifications
Powered by Bioz